$OCX News
Last published 5mo ago
- 5mo agoOCXIPAInterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of DirectorsPR NewswireInterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions,...
- 1y agoOCXIMDXOncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to NashvilleGlobeNewswireNew name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at
- 1y agoOCXMedicare Boosts Reimbursement for Oncocyte's Flagship TechnologyGlobeNewswireNew price of $2,753 for the GraftAssureCore™ assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for prospective
- 1y agoOCXOncocyte Reports Q1 2025 Results and Business ProgressGlobeNewswireQ1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are now using our
- 1y agoOCXOncocyte to Release First Quarter 2025 Results on May 12, 2025GlobeNewswireIRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes
- 1y agoOCXOncocyte Provides Positive Update on Clinical Trial ProgressGlobeNewswireCentral Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant
- 1y agoOCXOncocyte's Proprietary Assay Demonstrates Long-Term Clinical ValidityGlobeNewswireRobust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in BerlinSupports market expansion for testing of high-risk patient populationNew findings advance understanding of
- 1y agoOCXOncocyte to Participate in 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireIRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James
- 1y agoBIOOCXOncocyte Reports Successful 2024; Sets Stage for 2025 CatalystsGlobeNewswireQ4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded clinical kitted product
- 1y agoOCXOncocyte to Release Fourth Quarter 2024 Results on March 24, 2025GlobeNewswireIRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market
- 1y agoOCXOncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceGlobeNewswireIRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea
- 1y agoBIOOCXOncocyte Prices $29.1 Million Equity OfferingGlobeNewswireProceeds Expected to Fund Transplant Assay Through FDA IVD Clearance and Commercial LaunchStrategic Partner Bio-Rad Invests, Boosts Support for Trial and Commercialization IRVINE, Calif., Feb. 10, 2025 (GLOBE
- 1y agoOCXOncocyte Appoints Dr. Paul Billings as Consulting Chief Medical OfficerGlobeNewswireDr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and
- 1y agoOCXOncocyte Expands Market Opportunity for VitaGraft™ KidneyGlobeNewswireMedicare coverage expanded following study showing that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA)MolDX confirms
- 1y agoOCXOncocyte to Participate in "J.P. Morgan Week" and Host Investor MeetingsGlobeNewswireIRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James
- 1y agoOCXOncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New StudyGlobeNewswireIRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper
- 1y agoOCXOncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study AffirmsGlobeNewswireOncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in
- 1y agoOCXOncoCyte Corporation (OCX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoOCXOncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025GlobeNewswireTransplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phaseFDA pre-submission process for
- 2y agoOCXOncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12GlobeNewswireIRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday,
- 2y agoOCXOncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los AngelesGlobeNewswireIRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD
- 2y agoOCXOncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical TrialGlobeNewswireResults published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO's utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a
- 2y agoOCXOncocyte Signs Leading Transplant Centers in US and GermanyGlobeNewswireGraftAssure™ research assay adopted by two research hospitals that are top-five-in-country by organ transplant volumeCompany clears first stage gate in clinical product development process and has submitted a
- 2y agoOCXOncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesGlobeNewswireIRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX) ("Oncocyte" or the "Company"), a diagnostics technology company, today announced that it has entered into a securities purchase
- 2y agoOCXPRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics TechnologyGlobeNewswireNEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an illuminating interview with Oncocyte (NASDAQ:OCX) CFO Andrea S. James, who sheds light on her personal career path and the
- 2y agoOCXOncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series StudyGlobeNewswireIRVINE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a molecular diagnostics technology company, announced the recent publication of a case series of two kidney transplant patients who were
- 2y agoOCXOncoCyte Corporation (OCX) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoAXONBIOOCXOncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 ResultsGlobeNewswireInterest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp.
- 2y agoOCXOncocyte Announces August Investor Conferences ParticipationGlobeNewswireIRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following
- 2y agoOCXOncocyte to Announce Second Quarter 2024 Financial Results on August 8GlobeNewswireIRVINE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announced today that the company will release its second quarter 2024 financial results on Thursday,
- 2y agoOCXMedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in "Take Advantage of the Moment" EpisodeGlobeNewswireHOLLAND, Mich., July 11, 2024 (GLOBE NEWSWIRE) -- MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ:OCX) CEO Josh Riggs in its latest episode,
- 2y agoOCXOncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership MoveGlobeNewswireNEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's
- 2y agoAXONOCXOncocyte Appoints Andrea James as Chief Financial OfficerGlobeNewswireIRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of
- 2y agoOCXBreakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft StudyGlobeNewswireNEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte's (NASDAQ:OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the
- 2y agoOCXFavorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of MedicineGlobeNewswireLate-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with claims expansion
- 2y agoOCXOncoCyte Corporation (OCX) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoOCXOncocyte Reports First Quarter 2024 Financial ResultsGlobeNewswireIRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Announced
- 2y agoOCXOncocyte to Announce First Quarter 2024 Financial ResultsGlobeNewswireIRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday,
- 2y agoOCXPRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics MarketplaceGlobeNewswireNEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Oncocyte Corporation's Chief Executive Officer, Josh Riggs, as the company works to disrupt the mature
- 2y agoOCXOncoCyte Corporation (OCX) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoOCXOncocyte Reports Full Year 2023 Financial ResultsGlobeNewswireIRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad
- 2y agoOCXOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesGlobeNewswireIRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX) ("Oncocyte" or the "Company"), a precision diagnostics company, today announced that it has entered into definitive securities
- 2y agoBIOOCXOncocyte and Bio-Rad Partner on Global Launch of Transplant AssayGlobeNewswire- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance
- 2y agoOCXOncocyte to Announce Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireIRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial
- 2y agoOCXOncocyte to Present at the Sequire Investor Summit in Puerto RicoGlobeNewswireIRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire
- 2y agoOCXOncocyte Begins FDA Submissions Process for VitaGraft Transplant AssaysGlobeNewswire- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte
- 3y agoOCXOncocyte Reports Third Quarter 2023 Financial ResultsGlobeNewswire-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision
- 3y agoOCXOncocyte to Announce Third Quarter 2023 Financial ResultsGlobeNewswireIRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9,
- 3y agoOCXOncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierACCESS NewswireInterventional study compares VitaGraft to current transplant rejection monitoring protocolsOncocyte's VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring
- 3y agoOCXOncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceACCESS NewswireCEO Josh Riggs will be meeting with registered investors on September 11-12, 2023IRVINE, CA / ACCESSWIRE / September 6, 2023 / Oncocyte Corporation , a precision diagnostics company, today announced that it